Bellerophon Therapeutics (NASDAQ:BLPH) Now Covered by StockNews.com

Analysts at StockNews.com began coverage on shares of Bellerophon Therapeutics (NASDAQ:BLPHGet Free Report) in a report issued on Tuesday. The firm set a “hold” rating on the biotechnology company’s stock.

Bellerophon Therapeutics Stock Performance

Shares of BLPH opened at $0.04 on Tuesday. The company has a 50-day simple moving average of $0.04 and a 200-day simple moving average of $0.05. The firm has a market capitalization of $440,388.00, a P/E ratio of -0.04 and a beta of 0.70. Bellerophon Therapeutics has a 52 week low of $0.03 and a 52 week high of $0.41.

About Bellerophon Therapeutics

(Get Free Report)

Bellerophon Therapeutics, Inc, a clinical-stage therapeutics company, focuses on the development of products for the treatment of cardiopulmonary diseases in the United States. Its primary product is INOpulse, a proprietary pulsatile nitric oxide delivery platform for the treatment of pulmonary hypertension.

Read More

Receive News & Ratings for Bellerophon Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Bellerophon Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.